Gene Therapy Application Articles & Analysis
8 news found
CD Formulation, a leading provider of innovative pharmaceutical formulation services, has recently launched a comprehensive range of microsphere and microneedle solutions for pharmaceutical and biotech applications. The newly introduced solutions are focused on long-acting controlled-release microspheres and phase-transition microneedle patches, to meet the growing demand for ...
“In addition, positive study outcomes from our cell & gene therapy platforms offer a potential upside that is hard to quantify exactly today but can reach multi-billion Euro ...
ByBayer AG
This further expands the GlycoConnect™ ADC tool kit by significantly enhancing the versatility across cytotoxic payloads and supports further expansion into antibody-based targeted gene therapy and immune cell engager ...
The product manager of the company is excited to launch the Gene Therapy Products Characterization service to help clients overcome the challenges of gene therapy analytical development, which include characterization, quality control, and the need to meet increasingly demanding regulatory expectations. Gene ...
Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announced it will hold a webinar entitled "Expert Perspectives: Immuno Gene & Cell Therapy for the Treatment of Solid Tumors" on Thursday, April 28, 2022 at ...
Company closes additional $22.6 million in new financing Proceeds will fund initiation of new clinical trial for lead gene therapy candidate XC001 as adjunctive therapy for patients undergoing coronary artery bypass graft surgery XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of ...
“Through its cell therapy research platforms, deep clinical development experience, and industrial manufacturing capabilities, MD Anderson is a best-in-class collaborator to advance and accelerate cutting-edge cell ...
Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies, today announced that Bristol Myers Squibb (NYSE:BMY) has exercised its option to an exclusive worldwide license to a cell therapy candidate based on Obsidian’s cytoDRiVE™ technology for the controlled expression of the ...